


Shaperon Publishes Efficacy of Next-Generation Cancer Immunotherapy in International Journal

Published in an international journal, the next-generation cancer immunotherapy shows 91.2% tumor growth inhibition and 97% metastasis prevention

RESEARCH TRIANGLE PARK, NC, UNITED STATES, July 22, 2024 /EINPresswire.com/ -- Hudson Therapeutics announced that Shaperon, Inc. (Kosdaq 378800, CEO Seung-Yong Seong), a biotech company specializing in innovative immune therapeutics and a headquarter of Hudson in Korea, has published outstanding preclinical results of its next-generation cancer immunotherapy targeting cancer stem cells in the international journal 'Biomedicine & Pharmacotherapy' (impact factor 7.5). This immunotherapy technology is being developed in collaboration with researchers from Seoul National University College of Medicine.

The cancer immunotherapy targeting cancer stem cells was found to not only activate the proliferation of cancer-killing 'T cells' in mouse tumor models but also increase the production of 'interferon-y,' which boosts immune responses.



Notably, it demonstrated an impressive 91.2% inhibition of melanoma growth and a 97% prevention of lung metastasis.



We expect it to be an excellent alternative to existing immune checkpoint inhibitors, which have low clinical remission rates and frequent recurrences, through new drug development."

Dr. Seung-Yong Seong, CEO of Shaperon

Shaperon's announced cancer stem cell target antigen is expressed in the stem cells of various cancers, including colon, breast, and lung cancers, and is a protein associated with cancer proliferation and resistance to immunotherapy.

The research team believes that removing cancer stem cells through the target antigen can induce a sufficient anti-cancer immune response, making effective cancer treatment possible.

Cancer stem cells suppress anti-cancer immune responses

and increase resistance to immune checkpoint inhibitors. Due to this, efforts to effectively eliminate cancer stem cells to improve the efficacy of immune checkpoint inhibitors have continued, but there are few commercialized cases.

Dr. Seung-Yong Seong, CEO of Shaperon stated, "The significance of this next-generation cancer immunotherapy technology lies in the newly discovered promising target antigen that can efficiently eliminate cancer stem cells, evolving immuno-oncology technology to the next level. We expect it to be an excellent alternative to existing immune checkpoint inhibitors, which have low clinical remission rates and frequent recurrences, through new drug development." He added, "We anticipate that combining this with existing immune checkpoint inhibitors to remove cancer stem cells with immune resistance can drastically reduce not only tumor recurrence but also the possibility of metastasis. Based on these preclinical results, we will accelerate the development of nanobody technology for cancer stem cell target antigens to maximize anticancer treatment effects."

Ms. Janice Marie McCourt, CEO of Hudson Therapeutics said "We are thrilled to share the groundbreaking results from Shaperon's next-generation cancer immunotherapy therapeutic. This publication in a prestigious international journal underscores the potential of our innovative approach to target and eliminate cancer stem cells, significantly improving treatment outcomes for patients. The promising preclinical data paves the way for advanced clinical trials in orphan indications to start and future collaborations with partners, solidifying our commitment to revolutionizing cancer treatment. We look forward to further developing this therapeutic to offer more effective and targeted cancer therapies."

ABOUT SHAPERON

Shaperon is a clinical-stage biotech company developing novel inflammasome inhibitors. Its unique mechanism of action of GPCR19-P2X7 modulation suppresses a broad spectrum of inflammatory cytokines including IL-1 β , IL-18, IL-6, and TNF- α by controlling both the priming and activation phases of the inflammasome, whereas conventional approaches are designed to

suppress only the activation phase. With this unique and novel modality, which is best suited to address complex immune-mediated inflammatory disorders, Shaperon is currently developing multiple clinical programs in atopic dermatitis, Alzheimer's disease, and COVID-19 pneumonia in addition to pre-clinical pipelines, including NASH and obesity programs.

ABOUT HUDSON THERAPEUTICS

Hudson Therapeutics, a US subsidiary of Shaperon, was founded and incorporated in the US in 2023 to lead global clinical trials, investor relations, commercial strategy, and business development of assets from Shaperon. Hudson also plans to develop Shaperon's early-stage assets in the future.

Ellie Jung Hudson Therapeutics, Inc, US Subsidiary of Shaperon email us here Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/728926159

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.